Oxford BioMedica Wins Licensing Deal of the Year
7 December 2007, London, Manchester, Munich: Clients represented by College Hill’s Life Sciences team, the leader in life science PR and communications, had a strong presence at the 3rd Annual Scrip Awards ceremony held on 4th December at the London Hilton on Park Lane. Three clients (Ablynx, HRA Pharma and Oxford BioMedica) were shortlisted for six nominations. On the night, Oxford BioMedica, a leading UK-based gene therapy company, won the Licensing Deal of the Year award.
Oxford BioMedica won the award for its exclusive global licensing agreement with Sanofi-Aventis to develop and commercialise TroVax® for the treatment and prevention of cancer. The win closely follows Oxford BioMedica receving the Achievement of the Year award at techMARK Awards Dinner last month.
Oxford BioMedica was also shortlisted in two other categories at the Scrip Awards: Biotech Company of the Year and Management Team of the Year.
Ablynx, a Belgium-based biopharmaceutical company focused on the discovery and development of Nanobodies®, was a finalist for Biotech Company of the Year. Its Chairman and CEO, Dr Edwin Moses, was shortlisted for Executive of the Year.
HRA Pharma, a Paris-based private pharmaceutical company providing innovative medicines and products for women’s and reproductive health, endocrine diseases and cell-based therapies, was shortlisted for the Corporate Social Responsibility award. Its humanitarian programme includes activities ranging from women’s health education programmes in developing countries, to political lobbying, healthcare staff training or supplying drugs and medical devices free of charge.
Sue Charles, Managing Partner of College Hill’s Life Sciences team commented: “We are very proud of our clients’ strong presence at this year’s Scrip Awards. To be shortlisted for such prestigious awards is a testament to our client’s hard work and accomplishments. We are delighted that the Oxford BioMedica team was recognised once again for its sanofi-aventis deal.”
For further information:
Sue Charles, Managing Partner
UK: +44 (0)20 7457 2020/ +44 (0)7968 726 585
Australia: +61 (0)457 196 222